Blogs
ADCs represent a promising class of targeted therapies, and understanding the intricacies of their analysis is crucial for their successful development. In this blog, we address common questions to guide you through the various considerations involved in ADC research and testing. We will cover key topics related to the…
Blogs
Antibody drug conjugates (ADCs) are important targeted therapies in oncology. These are complex moieties consisting of a cell-targeting antibody combined with an active payload through a chemical linker. Key Components to Monitor in PK Studies Two significant components to monitor for PK studies are the (1) intact antibody drug conjugate…
December 10
- December 10
KCAS Bio is excited to sponsor the upcoming Pharmaceutical & BioScience Society (PBSS) workshop “Antibody-Drug Conjugates from Discovery to Development: Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical Design and Intellectual Property,” on December 10th from 8:45am – 5:30pm PST in San Diego, California at the Hyatt Regency – La Jolla. Showcasing…
Blogs
In the complex and dynamic bioanalytical landscape of antibody-drug conjugate (ADC) services, where often time is critical and every research dollar counts, hybrid technology is quickly emerging as a game-changer. Hybrid offers a spectrum of advantages that redefine traditional approaches to bioanalytical ADC drug development. At the forefront of these…
Blogs
If you are part of the Biotech/Pharma community, you may be familiar with the (J.P. Morgan) JPM Healthcare Conference that takes place annually in January and typically in San Francisco. This was the 42nd Annual JPM Healthcare Conference and it is the world’s largest healthcare symposium. This year the mood…